ARTICLE | Clinical News
DSMB recommends continuation of Actelion trials
August 31, 2000 7:00 AM UTC
An independent Data and Safety Monitoring Board (DSMB) recommended continuation of Actelion's Phase III RITZ study of tezosentan intravenous endothelin receptor antagonist to treat acute heart failure...